Skip to main content
Industry News
Study: DSP-6952 effective in IBS-C
6/29/2020

Patients with constipation-predominant irritable bowel syndrome were able to tolerate up to 40 mg of DSP-6952 daily, according to a study published in Alimentary Pharmacology and Therapeutics. More patients who took 30 mg reported at least one spontaneous bowel movement, but those who took 40 mg met the endpoints of spontaneous bowel movements and pain reduction for a minimum of nine weeks.

Full Story: